In the published article^[@b1]^, some errors appeared on page 238, **[Figure 1](#Figure1){ref-type="fig"}**, and reference list. The editors and the authors apologize for the errors and for any confusion theymay have caused. On page238, the sentence of \"affecting 20% and 17.5% of cases\" should be changed to \"and that inactivation of these genesoccurs in 17.5% and 20% of cases\".

The correct **[Figure 1](#Figure1){ref-type="fig"}** should be as following.

![Common molecular events identified in HGS OC, including genetic and epigenetic defects in HRR pathway components (right).](cbm-14-2-196-1){#Figure1}
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